The pharmaceutical giant Pfizer will pay nearly $60 million to resolve charges that a company it acquired paid kickbacks so ...

Today in History for Jan. 29: ...

In a report released on January 21, Akash Tewari from Jefferies reiterated a Buy rating on Pfizer (PFE – Research Report). The company’s shares ...

Bernstein analyst Courtney Breen maintained a Hold rating on Pfizer (PFE – Research Report) today and set a price target of $32.00. The ...

Pfizer will pay $59.7 million to resolve charges that a company it acquired defrauded Medicare and other healthcare programs ...

Pfizer Inc. closed 16.17% below its 52-week high of $31.54, which the company achieved on July 30th.

Bourla said the experts were helping Pfizer "make better and more sound decisions," and the company could start a late-stage study of its drug, danuglipron, in the second half of this year.

The sale represents nearly 7.7% of issued share capital of Haleon, which was created by the merger of GSK and Pfizer's ...

Pfizer (PFE.N), opens new tab will sell shares worth 2.50 billion pounds ($3.05 billion) in Haleon (HLN.L), opens new tab, lowering its stake in the British consumer healthcare company to about 7. ...

(Reuters) -U.S. drugmaker Pfizer is going "all in" to develop its experimental obesity drug and has been recruiting more ...

Pfizer Inc. closed 17.53% short of its 52-week high of $31.54, which the company reached on July 30th.